Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

TransThera Sciences' YOCHANRA (Tinengotinib) Receives First Prescription in China – World's First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma
CompanyDrug

TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma

XtalPi's LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology
Others

XtalPi’s LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology

Huadong Medicine's Sinclair Secures Exclusive China Collaboration for Maybio's iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet
CompanyDeals

Huadong Medicine’s Sinclair Secures Exclusive China Collaboration for Maybio’s iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership
CompanyDeals

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership

Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion
CompanyDeals

Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion

HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing
CompanyDeals

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

Haisco's HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma
CompanyDrug

Haisco’s HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma

Astellas' PADCEV Plus Keytruda Receives Positive CHMP Opinion – Perioperative Muscle‑Invasive Bladder Cancer Regimen Nears EU Approval
CompanyDrug

Astellas’ PADCEV Plus Keytruda Receives Positive CHMP Opinion – Perioperative Muscle‑Invasive Bladder Cancer Regimen Nears EU Approval

Novo Nordisk's FREHEMGO (Denecimig) Receives Positive CHMP Opinion – Next‑Generation Hemophilia A Prophylaxis Nears EU Authorization
CompanyDrug

Novo Nordisk’s FREHEMGO (Denecimig) Receives Positive CHMP Opinion – Next‑Generation Hemophilia A Prophylaxis Nears EU Authorization

Nutshell Therapeutics' NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2
CompanyDrug

Nutshell Therapeutics’ NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2